InsidersTradesSigma
Follow the TCR2 THERAPEUTICS INC. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, TCR2 THERAPEUTICS INC. has logged 37 reports. The latest transaction was disclosed on 14 February 2024 (J). Among the most active insiders: Menzel Garry E. The full history is free.
37
Insider Decl.
n/a
Thresholds
€281,616
4 ops.
Buy Volume
€61,715
16 ops.
Sell Volume
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 February 2024
Declarations37 total
4,394,800 sharesCommon StockSEC:0001415889-24-003784:0
3,370,982 shares0Common StockSEC:0001209191-23-034346:0
4,158,964 shares0Common StockSEC:0001209191-23-034340:0
4,158,964 shares0Common StockSEC:0001209191-23-034343:0
304,001 shares0Common StockSEC:0001209191-23-034336:0
132,729 sharesCommon StockSEC:0001104659-23-067053:0
109,459 sharesCommon StockSEC:0001104659-23-067068:0
48,745 sharesCommon StockSEC:0001104659-23-067051:0
24,092 sharesCommon StockSEC:0001104659-23-067064:0
50,000 shares@ US$1.7228.5% of flowCommon StockSEC:0001209191-23-033041:0
Canonical exit: 23 Aug 2023 (T+90)
178,269 shares@ US$0.74100.0% of flowCommon StockSEC:0001209191-23-031888:0
178,269 shares@ US$0.74100.0% of flowCommon StockSEC:0001209191-23-031889:0
38,765 shares@ US$1.9524.6% of flowCommon StockSEC:0001209191-23-029527:0
Canonical exit: 9 Aug 2023 (T+90)
57,073 shares@ US$1.9535.9% of flowCommon StockSEC:0001209191-23-028565:0
Canonical exit: 6 Aug 2023 (T+90)
18,513 shares@ US$1.8511.0% of flowCommon StockSEC:0001209191-23-027833:0
Canonical exit: 1 Aug 2023 (T+90)
2,792 shares@ US$1.12813.1% of flowCommon StockSEC:0000899243-22-038381:0
1,561 shares@ US$1.13133.2% of flowCommon StockSEC:0000899243-22-038384:0
10,325 shares@ US$1.13123.8% of flowCommon StockSEC:0000899243-22-038380:0
4,461 shares@ US$1.1326.0% of flowCommon StockSEC:0000899243-22-038387:0
3,928 shares@ US$1.28326.3% of flowCommon StockSEC:0000899243-22-038102:0
1,378 shares@ US$1.28233.5% of flowCommon StockSEC:0000899243-22-038096:0
2,457 shares@ US$1.28213.2% of flowCommon StockSEC:0000899243-22-038097:0
9,111 shares@ US$1.28224.0% of flowCommon StockSEC:0000899243-22-038098:0
2,302 shares@ US$1.37313.2% of flowCommon StockSEC:0000899243-22-037940:0
1,291 shares@ US$1.36833.3% of flowCommon StockSEC:0000899243-22-037942:0
25 of 37 declarations
关于 TCR2 THERAPEUTICS INC.
TCR2 Therapeutics Inc. 是一家美国生物技术公司，在美国 NASDAQ 上市，专注于针对实体瘤的下一代细胞疗法和免疫疗法。在工程化 T 细胞科学快速发展的时期建立，该公司将自己定位为新型 T 细胞疗法的临床阶段开发商，这些疗法旨在识别肿瘤相关抗原。其总部位于马萨诸塞州剑桥市，该地是美国最重要的生物技术集群之一。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000095017023009312/tcrr-20221231.htm?utm_source=openai)) 从运营角度来看，TCR2 不是商业阶段公司。它主要是一个研究开发组织，价值创造与其临床管线、转化数据和监管进展相关，而非产品销售。其战略围绕针对实体瘤的工程化 T 细胞方法展开，这一治疗领域因肿瘤异质性、肿瘤微环境和实现持久反应的挑战而比血液系统恶性肿瘤更具难度。从实际股权分析的角度来看，该公司应被视为管线驱动型生物技术公司，其估值取决于临床里程碑、资本获取和战略合作。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000095017023009312/tcrr-20221231.htm?utm_source=openai)) 在竞争方面，TCR2 在一个拥挤且高度创新的领域内运营，该领域包括规模更大的生物技术集团和许多小市值细胞疗法开发商。其差异化来自于其在实体瘤中抗原特异性 T 细胞参与的关注以及推进旨在解决高度未满足医疗需求的项目。因此，该公司的商业模式是典型的早期至中期阶段生物技术：没有有意义的商业产品基础、高研发强度以及围绕试验结果的重大二元风险。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000095017023009312/tcrr-20221231.htm?utm_source=openai)) 一项重大企业事件重塑了这一局面。2023 年 3 月，TCR2 宣布与 Adaptimmune Therapeutics plc 进行全股票战略合并，该合并于 2023 年 6 月 1 日完成。该交易实际上结束了 TCR2 作为独立上市公司的生命，并将其资产整合到 Adaptimmune 更广泛的实体瘤细胞疗法平台中。([sec.gov](https://www.sec.gov/Archives/edgar/data/1750019/000110465923030597/tm238549d4_425.htm?utm_source=openai)) 对于今天分析 SEC 第 4 表格内部人士活动的投资者来说，TCR2 最好被理解为历史发行人而非活跃的独立上市名称。最相关的要点是其作为 NASDAQ 上市美国生物技术公司的前身份、其马萨诸塞州剑桥市的基地、其对实体瘤工程化 T 细胞疗法的关注，以及 2023 年合并的重要性，该合并将该公司整合到 Adaptimmune 中。([adaptimmune.com](https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/247/adaptimmune-announces-completion-of-strategic-combination?utm_source=openai))
